Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.62 |
| ▸ | MAPT | P10636 | 8/20 | 0.62 |
| ▸ | HPGD | P15428 | 6/20 | 0.62 |
| ▸ | GAA | P10253 | 4/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | CASP1 | P29466 | 1/20 | 0.62 |
| ▸ | CASP7 | P55210 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12693538 | 0.89 | KDM4E (0.66) | KDM4EALDH1A1MAPTHPGDGAA | |
| SCHEMBL15862062 | 0.86 | KDM4E (0.62) | KDM4EALDH1A1MAPTHPGDGAA | |
| SCHEMBL11326977 | 0.86 | MAPT (0.57) | KDM4EALDH1A1MAPTHPGDGAA | |
| SCHEMBL12788047 | 0.84 | CA1 (0.53) | KDM4EALDH1A1MAPTHPGDGAA | |
| SCHEMBL20594386 | 0.83 | MAPT (0.58) | KDM4EALDH1A1MAPTHPGDGAA | |
| SCHEMBL6299259 | 0.83 | KDM4E (0.58) | KDM4EALDH1A1MAPTHPGDGAA | |
| SCHEMBL27862364 | 0.83 | KDM4E (0.58) | KDM4EALDH1A1MAPTHPGDGAA | |
| SCHEMBL13841059 | 0.82 | KDM4E (0.57) | KDM4EALDH1A1MAPTHPGDGAA | |
| SCHEMBL543687 | 0.81 | KDM4E (0.55) | KDM4EALDH1A1MAPTHPGDGAA | |
| SCHEMBL30204346 | 0.81 | KDM4E (0.55) | KDM4EALDH1A1MAPTHPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118239926-A | TLR7 and 8 inhibitors, preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20230406830-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | Valo Health, LLC | 2023-12-21 | — | — | US | disclosed |
| US-11655269-B2 | Prodrug-type anticancer agent using cancer-specific enzymatic activity | THE UNIVERSITY OF TOKYO (JP) | 2023-05-23 | — | — | US | disclosed |
| US-11414392-B2 | [6,6] fused bicyclic HDAC8 inhibitors | VALO HEALTH, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-20210139439-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | VALO HEALTH, INC. | 2021-05-13 | — | — | US | disclosed |
| US-20210139439-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | VALO HEALTH, INC. | 2021-05-13 | — | — | US | disclosed |
| EP-3344600-B1 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2021-02-24 | — | — | EP | disclosed |
| US-20200399305-A1 | PRODRUG-TYPE ANTICANCER AGENT USING CANCER-SPECIFIC ENZYMATIC ACTIVITY | THE UNIVERSITY OF TOKYO (JP) | 2020-12-24 | — | — | US | disclosed |
| US-10829460-B2 | [6,6] fused bicyclic HDAC8 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10829460-B2 | [6,6] fused bicyclic HDAC8 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20170064961-A1 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170066729-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | Valo Health, LLC | 2017-03-09 | — | — | US | disclosed |
| US-20170066729-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | Valo Health, LLC | 2017-03-09 | — | — | US | disclosed |
| US-20170066729-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | Valo Health, LLC | 2017-03-09 | — | — | US | disclosed |
| WO-2017040963-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017040963-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20070032518-A1 | Compounds and methods of use | AMGEN INC. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1478645-A2 | QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS | Amgen Inc. (US) | 2004-11-24 | — | — | EP | disclosed |
| US-6822097-B1 | THIAZOLE-SUBSTITUTED QUINOLINE DERIVATIVES; ANTICARCINOGENIC AGENTS, ANTISTROKE AGENTS; APOPTOSIS AND CELL PROLIFERATION TREATMENT; NERVOUS SYSTEM DISORDERS | AMGEN, INC. | 2004-11-23 | — | — | US | disclosed |
| WO-2003066630-A2 | QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS | AMGEN INC. (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655269-B2 | Prodrug-type anticancer agent using cancer-specific enzymatic activity | GUSB, NTPCR, FOLH1 | KDM4E 2258/4885ALDH1A1 168/4885MAPT 4611/4885 |
| US-20170064961-A1 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO | ACHE, DDT, MLYCD | KDM4E 1609/4885ALDH1A1 443/4885MAPT 3431/4885 |
| US-20170066729-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | KDM4E 192/4885ALDH1A1 1338/4885MAPT 135/4885 |
| US-20230406830-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | KDM4E 192/4885ALDH1A1 1338/4885MAPT 135/4885 |
| US-20210139439-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | KDM4E 192/4885ALDH1A1 1338/4885MAPT 135/4885 |
| US-20070032518-A1 | Compounds and methods of use | BAX, BAD, CASP3 | KDM4E 2614/4885ALDH1A1 282/4885MAPT 1974/4885 |
| US-11414392-B2 | [6,6] fused bicyclic HDAC8 inhibitors | HDAC8, HDAC3, HDAC2 | KDM4E 192/4885ALDH1A1 1338/4885MAPT 135/4885 |
| US-10829460-B2 | [6,6] fused bicyclic HDAC8 inhibitors | HDAC8, HDAC1, HDAC2 | KDM4E 215/4885ALDH1A1 1573/4885MAPT 2104/4885 |
| US-20200399305-A1 | PRODRUG-TYPE ANTICANCER AGENT USING CANCER-SPECIFIC ENZYMATIC ACTIVITY | GUSB, NTPCR, FOLH1 | KDM4E 2258/4885ALDH1A1 168/4885MAPT 4611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.